Diversified Trust Co Decreases Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Diversified Trust Co trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 55.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 827 shares of the medical instruments supplier’s stock after selling 1,038 shares during the period. Diversified Trust Co’s holdings in West Pharmaceutical Services were worth $327,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Evoke Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at about $7,770,000. International Assets Investment Management LLC lifted its position in shares of West Pharmaceutical Services by 13,230.0% during the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after buying an additional 18,522 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of West Pharmaceutical Services by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after buying an additional 104,740 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of West Pharmaceutical Services by 39.8% during the fourth quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock valued at $48,750,000 after buying an additional 39,392 shares during the last quarter. Finally, UBS Group AG lifted its position in shares of West Pharmaceutical Services by 15.8% during the fourth quarter. UBS Group AG now owns 82,290 shares of the medical instruments supplier’s stock valued at $28,976,000 after buying an additional 11,245 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at West Pharmaceutical Services

In related news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Silji Abraham sold 1,800 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $320.90 on Friday. The firm has a market capitalization of $23.37 billion, a P/E ratio of 42.34, a PEG ratio of 5.70 and a beta of 1.00. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average price of $338.20 and a 200 day moving average price of $359.56. West Pharmaceutical Services, Inc. has a 52 week low of $310.00 and a 52 week high of $415.73.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. The firm had revenue of $695.40 million during the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. West Pharmaceutical Services’s revenue was down 3.0% on a year-over-year basis. During the same period last year, the firm posted $1.98 EPS. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is currently 10.55%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.